Clinical Trial Update: Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Yttrium-90 SMT-487 in patients with refractory or recurrent cancers across multiple tumor types; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors
• Breast Cancer
• Gastrointestinal Carcinoid Tumors
• Islet Cell Tumor
• Lung Cancer
• Lymphoma
• Melanoma
• Neoplastic Syndrome

Drugs mentioned

• Yttrium-90 SMT-487 (yttrium-90 SMT-487)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Brain and Central Nervous System Tumors, Breast Cancer | Phase 1 | Status: COMPLETED